Inflammatory bowel disease patients experiencing a loss of response to infliximab regain long-term response after undergoing granulocyte/monocyte apheresis: A case series
Authors:
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Treatment options for children and adolescents with inflammatory bowel disease: is granulomonocytapheresis an effective alternative to drug therapy?Expert Review of Gastroenterology & Hepatology, 2017
- Safety and Efficacy of Granulocyte/Monocyte Apheresis in Steroid-Dependent Active Ulcerative Colitis with Insufficient Response or Intolerance to Immunosuppressants and/or Biologics [the ART Trial]: 12-week Interim ResultsJournal of Crohn's and Colitis, 2016
- Systematic review with meta‐analysis: the efficacy of a second anti‐TNF in patients with inflammatory bowel disease whose previous anti‐TNF treatment has failedAlimentary Pharmacology & Therapeutics, 2015
- Crohn's disease complicated by hepatitis B virus successfully treated with the use of adsorptive depletion of myeloid lineage leucocytes to suppress inflammatory cytokine profileCytotherapy, 2014
- Comparison of efficacy, pharmacokinetics, and immunogenicity between infliximab mono‐ versus combination therapy in ulcerative colitisJournal of Gastroenterology and Hepatology, 2014
- Doubling the infliximab dose versus halving the infusion intervals in Crohnʼs disease patients with loss of responseInflammatory Bowel Diseases, 2012
- Review article: loss of response to anti-TNF treatments in Crohn’s diseaseAlimentary Pharmacology & Therapeutics, 2011
- Safety and Efficacy of Granulocyte and Monocyte Adsorption Apheresis in Paediatric Inflammatory Bowel Disease: A Prospective Pilot StudyJournal of Pediatric Gastroenterology and Nutrition, 2008
- Adacolumn, an Adsorptive Carrier Based Granulocyte and MonocyteApheresis Device for the Treatment of Inflammatory and RefractoryDiseases Associated with LeukocytesTherapeutic Apheresis and Dialysis, 2003
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002